The bivalent human papillomavirus adsorbed vaccine is effective in preventing cervical cancer, grade 2 or 3 cervical intraepithelial neoplasia (CIN2/3), and adenocarcinoma in situ, grade 1 cervical intraepithelial neoplasia (CIN1), due to high-risk types of human papillomavirus (HPV) 16 or 18.
Common adverse reactions to bivalent human papillomavirus adsorbed vaccine include fatigue, headache, myalgia, injection site pain, redness, swelling, and other symptoms.
Medication precautions: recommended for women aged 9 to 45 years, should be used with caution in lactating women, should be avoided in pregnant women, not recommended for concomitant vaccination with other vaccines, bivalent HPV adsorbed vaccine is contraindicated in patients who are allergic to the drug components in the bivalent HPV adsorbed vaccine.
If you need to use bivalent human papillomavirus adsorbed vaccine, please consult your doctor and strictly follow the doctor’s instructions.